Work

Figure S5 from Targeting c-Myc to Overcome Acquired Resistance of EGFR Mutant NSCLC Cells to the Third-Generation EGFR Tyrosine Kinase Inhibitor, Osimertinib

Year: 2023

Type: other

Abstract: BET inhibition with different BET inhibitor (A) or degrader (B) synergizes with osimertinib in decreasing the survival of osimertinib-resistant cell lines.

DOI: 10.1158/0008-5472.22429144

Authors: Lei Zhu, Zhen Chen, Hongjing Zang, Songqing Fan, Jiajia Gu, Guojing Zhang, Kevin D.-Y. Sun, Qiming Wang, Yong He, Taofeek K. Owonikoko, Suresh S. Ramalingam, Shi-Yong Sun

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361879321

Cites:

Cited by:

Related to: 10